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Abstract: Type IIα DNA topoisomerase (TopoIIα) is among the most important clinical 
drug targets for the treatment of cancer. Recently, the DNA repair protein Metnase was 
shown  to  enhance  TopoIIα  activity  and  increase  resistance  to  TopoIIα  poisons.  Using  
in vitro  DNA decatenation assays we show that neoamphimedine potently  inhibits 
TopoIIα-dependent DNA decatenation in the presence of Metnase.  Cell proliferation 
assays demonstrate that neoamphimedine can inhibit Metnase-enhanced cell growth with 
an IC50  of 0.5  µM. Additionally, we find that the apparent Km  of  TopoIIα  for  ATP 
increases linearly with higher concentrations of neoamphimedine, indicating   
ATP-competitive inhibition, which is substantiated by molecular modeling. These findings 
support the continued development of neoamphimedine as an anticancer agent, particularly 
in solid tumors that over-express Metnase. 
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1. Introduction 
Type IIα DNA topoisomerase (TopoIIα) plays a critical role in cell cycle progression by relieving 
various types of topological strain induced in DNA double strands during replication, transcription, 
and chromosome segregation, making it a crucial target for chemotherapy in several cancers [1–3]. 
The clamp-shaped nuclear homodimer causes transitory double-stranded breaks in DNA, allowing it to 
pass a second double strand through before re-ligating the broken strand, fueled by ATP hydrolysis[4]. 
This process generates an intermediate complex in which TopoIIα is covalently bound to the cleaved 
DNA, known as the cleaved complex [3,5]. Conventional TopoIIα poisons, such as doxorubicin and 
etoposide, act by stabilizing this complex, leading to its accumulation, DNA lesions, and ultimately, 
apoptosis. However, accumulation of this cleaved complex can lead to chromosomal translocations 
contributing to adverse side effects including secondary malignancies  [2].  One of the exclusive 
functions of TopoIIα is to decatenate (disentangle) sister chromatids before segregation [5]. Metnase, a 
recently identified double-strand break repair factor, interacts with TopoIIα and this interaction has 
been shown to enhance TopoIIα-dependent DNA decatenation [6]. Recent studies of this interaction 
show that Metnase can promote tumor cell growth in the presence of conventional TopoIIα poisons, 
which may be an important factor in multidrug resistance (MDR) in malignant cancers over-expressing 
Metnase [7,8]. Therefore TopoIIα inhibitors that do not stabilize DNA-TopoIIα complexes, but instead 
inhibit ATP hydrolysis, could provide great therapeutic benefit, especially where resistance to 
conventional TopoIIα poisons is observed. 
Neoamphimedine and amphimedine (Figure 1) are marine alkaloids from Xestospongia sp. While 
amphimedine is biologically inactive as an antitumor agent, neoamphimedine  is known to inhibit 
TopoIIα and has been shown to be as effective as etoposide at inhibiting the growth of xenograft 
tumors in mice [9]. Though neoamphimedines  exact mechanism of inhibition is not yet fully 
understood, it has been demonstrated that neoamphimedine does not stabilize the cleaved complex; 
rather, it has been shown to induce TopoIIα-mediated catenation of plasmid DNA in vitro [9,10].  
Figure 1. The structures of neoamphimedine and amphimedine.  
 
In the present study we performed TopoIIα-dependent DNA decatenation and cellular proliferation 
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inhibit Metnase-enhanced  TopoIIα  activity  in vitro.  TopoIIα-dependent ATP hydrolysis inhibition 
assays suggest that neoamphimedine is an ATP-competitive inhibitor and in silico molecular modeling 
data supports this indicating that neoamphimedine can bind to the ATPase sites of TopoIIα. 
2. Results and Discussion 
2.1. In Vitro DNA Decatenation and Cell Proliferation Assays 
Neoamphimedine has been shown to induce DNA catenation in  vitro; however, the ability of 
neoamphimedine to inhibit TopoIIα mediated decatenation has not been assessed. In addition, Metnase 
has been shown to resist the action of TopoIIα poisons by interacting with TopoIIα and enhancing its 
decatenation activity in vitro. Thus, we conducted TopoIIα decatenation assays with neoamphimedine 
in the presence and absence of an activity-enhancing concentration of Metnase (Figure 2).  
Figure 2. Neoamphimedine inhibits Metnase-enhanced TopoIIα-dependent decatenation. 
(a) A representative TopoIIα-decatenation gel treated with neoamphimedine as indicated; 
and (b) in the presence of Metnase; (c) Percent inhibition curves generated from decatenation 
assays in triplicate. DNA markers are denoted as M1 (decatenated, linear and circular) and 
M2 (catenated). 
 
Neoamphimedine  inhibits  TopoIIα-dependent decatenation  with and without Metnase  over 
concentrations ranging from 0.5–30 μM. Unexpectedly, neoamphimedines potency increased in the Mar. Drugs 2011, 9  2400 
 
presence of Metnase, suggesting that TopoIIα-Metnase protein-protein interactions may increase the 
binding affinity of neoamphimedine for TopoIIα (Figure 2C). Previously we reported that the same 
concentration of Metnase blocks the action of clinically used TopoIIα drugs etoposide and doxorubicin 
(cleaved complex stabilizers), and ICRF-193 (closed clamp stabilizer) at concentrations that 
completely inhibit TopoIIα-dependent decatenation in the absence of Metnase [6–8].  
We then investigated the potential for Metnase-related MDR by comparing relative growth of 
HEK293 cells to HEK293 cells that over-express Metnase (HEK293-Metnase) in the presence of 
neoamphimedine and etoposide (Figure 3). HEK293-Metnase cells display increased proliferation and 
resistance to etoposide relative to HEK293 cells as reported (Figure 3B,C)  [6,8].  In contrast,   
over-expression of Metnase increases sensitivity of cells to neoamphimedine, evident at concentrations 
≥0.5  μM (Figure 3D,E), consistent with the results observed in our decatenation assays showing 
increased inhibition of TopoIIα-dependent decatenation with  neoamphimedine  in the presence of 
Metnase at concentrations of 0.5 μM or higher (Figure 2C). 
Figure  3. Neoamphimedine inhibits Metnase-enhanced cell proliferation. (a) Untreated 
HEK293 and HEK293-Metnase cell proliferation after 72 hours  relative to day 0;  
(b) Relative growth of etoposide treated HEK293 (IC50 = 0.6 µM) and HEK293-Metnase  
(IC50 = 0.4 µM) cells to untreated cells after 72 h; (c) Relative growth over the concentration 
range 1–4 µM emphasizing resistance to etoposide in HEK293-Metnase cells; (d) Relative 
growth of neoamphimedine treated HEK293 (IC50  = 0.8 µM) and HEK293-Metnase  
(IC50 = 0.5 µM) cells to untreated cells after 72 h; (e) Relative growth over the concentration 
range  1–4 µM emphasizing sensitivity to neoamphimedine  in HEK293-Metnase cells. 
Statistical significance was determined using the unpaired, two-tailed t-test analysis, where 
(*) denotes P ≤ 0.05. 
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2.2. Competitive Inhibition Studies with Neoamphimedine and TopoIIα 
Since neoamphimedine does not act as a TopoIIα poison it seemed likely that it binds TopoIIα at a 
different  site  than  classical  TopoIIα  poisons,  which  bind  near  the  DNA  binding  site  [2,11,12]. 
Furthermore, Metnase has also been shown to increase resistance to ICRF-193, a TopoIIα inhibitor 
that binds allosterically in proximity to the N-terminal ATPase site [8,13]. Given that TopoIIα must 
hydrolyze ATP during catalytic function we hypothesized that Metnase-TopoIIα interactions do not 
obstruct the N-terminal  ATPase  sites  of  TopoIIα  and  that  neoamphimedine  binds  to  this  site, 
circumventing Metnase-mediated MDR [14,15]. To test this hypothesis we first measured TopoIIα 
dependent  ATP  hydrolysis  in  the  presence  of  supercoiled  DNA,  recombinant  human  TopoIIα  and 
varying concentrations of neoamphimedine using the malachite green assay [16,17]. The results of the 
ATP hydrolysis studies are displayed in Figure 4. We found the Km of TopoIIα for ATP to be 390 ± 50 μM 
and Vmax of the catalysis to be 0.0087 ± 0.0004 pmol min
−1·U
−1, consistent with previously reported 
data [17]. Upon treatment with increasing concentrations of neoamphimedine, apparent Km increased 
linearly (R
2 = 0.94) while Vmax did not seem to be dose-responsive, indicative of a competitive mode 
of inhibition (Figure 4A). Substrate-dependent reaction velocity (Michaelis-Menten plot) is shown in 
(Figure 4B)  for reactions treated with 0 and 10  μM  neoamphimedine.  The nonlinear fit of the   
dose-response inhibition model is shown in (Figure 4C). Using 600 μM ATP, the IC50 was found to be 
2.0 ± 0.4 μM. Using the Cheng-Prusoff equation, the Ki was calculated to be 0.8 ± 0.3 μM. 
Figure 4. (a) A linear (R
2 = 0.94) increase in apparent Km is observed over the range of  
0 to 10 μM  concentrations of neoamphimedine, indicative of a competitive mode of 
inhibition; (b) Competitive inhibition studies with ATP depicting a shift in the apparent Km 
from 390 ± 50 to 790 ± 120 μM ATP. Using the unpaired, two-tailed t-test analysis, this 
shift in apparent Km was statistically significant (P = 0.010) while the Vmax for both curves 
was not  (P  = 0.186);  (c)  Dose  response  curve  for  the  inhibition  of  TopoIIα  ATPase 
function the IC50 is found to be 2 µM. All data represent means with SEM error bars. 
 
2.3. Computational Modeling of Neoamphimedine with TopoIIα 
To  further  investigate  how  neoamphimedine  binds  and  inhibits  TopoIIα  we  conducted 
computational docking studies. As predicted by our biological studies, the TopoIIα ATPase sites were 
identified as binding sites of neoamphimedine with favorable calculated binding energies. The results 
of the computational modeling are shown in Figure 5. The binding conformation of neoamphimedine Mar. Drugs 2011, 9  2402 
 
in the ATPase site of TopoIIα (calculated binding energy = −61.8 kcal/mol) mimics that of ATP, the 
natural substrate (Figure 5B,C). The key interactions observed with neoamphimedine are a network of 
hydrogen bonds with Ser148, Ser149, and Asn150, and with Asn91 through an ordered water 
molecule. Additionally, neoamphimedine is attracted to the ATPase site Mg
2+ through charge transfer 
pi-cation interactions. Molecular docking of the inactive isomer amphimedine in the ATPase site of 
TopoIIα (calculated binding energy = −39.4 kcal/mol) reveals why the position of the carbonyl group 
is so important (Figure 5D). When the carbonyl is in the 3-position, as in amphimedine, the hydrogen 
bond with Ser148 is lost. This repositions amphimedine in the ATPase site in a conformation where 
the ring system is perpendicular compared to the binding of neoamphimedine. As a result of this 
repositioning, pi-cation interactions observed with neoamphimedine are lost and there is an unfavorable 
steric interaction with the active site Mg
2+. Thus, the position of the E ring carbonyl of neoamphimedine 
is key to its potent biological activity.  
Figure  5. (a) The N-terminal ATPase domain  of TopoIIα; (b) Neoamphimedine (cyan 
carbon atoms) docked in the ATPase binding site  with  nearby residues (white carbon 
atoms). Orange lines denote pi-cation attractions. Hydrogen bonds are displayed as black 
dashes and coordination interactions are shown as light blue lines with Mg
2+ (blue sphere); 
(c) ATP (burgundy carbon atoms) docked in the ATPase binding site; (d) Amphimedine 
docked (green carbon atoms) in the ATPase binding site of TopoIIα.  
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2.4. Discussion 
MDR is a major problem associated with existing clinically used TopoIIα inhibitors [18]. The most 
common mode of clinical drug resistance is due to the ABCB1 gene product P-glycoprotein (Pgp) 
efflux pump [18,19]. Another mode of MDR is associated with alterations in topoisomerase II [19]. 
One mechanism of MDR involves  TopoIIα  phosphorylation  that results  in increased catalytic   
activity [3,19,20]. Likewise, TopoIIα has been shown to complex with numerous cellular proteins that 
can alter its function independently of phosphorylation, also leading to increased catalytic activity and 
MDR in multiple types of cancer [3,7,21]. The most successful TopoIIα inhibitors are poisons that act 
by stabilizing either the cleaved complex or the closed clamp complex with DNA, which lead to DNA 
damage and cytotoxicity. Cases of MDR to clinically used TopoIIα poisons are frequently observed, 
and the nonspecific DNA damage caused by these poisons is known to cause adverse side effects and 
secondary malignancies. Therefore, inhibitors of TopoIIα that do not stabilize TopoIIα-DNA complexes 
may have greater therapeutic value than current inhibitors.  
Neoamphimedine is a novel TopoIIα inhibitor that does not stabilize the cleaved complex [9]. Nor 
does it cause significant DNA strand breaks or intercalate into DNA at concentrations below 100  μM [22]. 
Neoamphimedine is not a substrate for Pgp-dependent MDR, and it has been shown to be as 
efficacious as current clinical TopoIIα poisons both in vitro as an inhibitor of TopoIIα and in vivo as an 
antitumor agent [9]. We show here that neoamphimedine inhibits TopoIIα ATPase function with an 
IC50 of 2 μM and a corresponding Ki of 0.8 ± 0.3 μM. Indicative of a competitive mode of inhibition, a 
linear increase in the apparent Km of TopoIIα for ATP is observed with increasing neoamphimedine 
concentrations (Figure 4).  
Neoamphimedine  inhibits  TopoIIα-dependent decatenation at low concentrations with 90% 
inhibition occurring at 30 μM (Figure 2A,C). These data agree with the reported cell based anti-tumor 
activity of neoamphimedine (IC50 values ranging from 1–6 μM) in various human tumor cell lines [9]. 
In the presence of the TopoIIα  enhancer Metnase (Figure 2B,C), neoamphimedine inhibits   
TopoIIα-dependent decatenation at all concentrations tested (0.5–30 μM). This result is significant 
because Metnase has been shown to block the action of traditional TopoIIα poisons in both cell-based 
and  in vitro  decatenation assays, including doxorubicin, etoposide, and ICRF-193, suggesting  that 
neoamphimedine could overcome Metnase-dependent MDR. 
Furthermore, in the presence of Metnase the inhibitory activity of neoamphimedine significantly 
increases in both in vitro decatenation assays (Figure 2) and cell based assays (Figure 3), suggesting 
that TopoIIα-Metnase protein-protein interactions may increase the binding affinity of neoamphimedine 
for TopoIIα. Neoamphimedine has been shown to induce DNA catenation at concentrations ≥91  μM 
and saturating concentrations of ATP (1 mM) [9,23]. Our findings indicate that under these conditions 
ATP would out-compete neoamphimedine for binding to TopoIIα;  however,  neoamphimedine  can 
induce  DNA  aggregation  at  relatively  high  concentrations  (≥91  μM) facilitating catenation in the 
presence of saturating ATP [9]. ATP hydrolysis has been shown to drive equilibrium to favor decatenation 
rather than catenation in the absence of DNA aggregation by a condensing agent, and at relatively low 
concentrations (≤50 μM) neoamphimedine does not induce DNA aggregation [9,24]. Therefore, we 
propose that the primary anti-tumor activity of neoamphimedine is the inhibition of TopoIIα through 
binding of the N-terminal ATPase sites and competitively inhibiting ATP hydrolysis. Mar. Drugs 2011, 9  2404 
 
3. Experimental Section  
3.1. General Experimental Procedures  
Except where otherwise indicated, all chemicals were purchased from a chemical supplier and used 
as received. All computational simulations were performed within the Discovery Studio
® software [25], 
and crystallographic coordinates were obtained from the RCSB protein databank [4]. Neoamphimedine 
preparation [26] and recombinant Metnase purification [27] were performed as previously described. 
3.2. DNA Decatenation Assay 
TopoIIα (TopoGen) was added to 70 ng of kinetoplast DNA (kDNA, TopoGen) comprising small 
interlocked supercoiled circular DNA in reaction buffer (50 mM Tris-HCl, pH 8.0, 120 mM KCl,  
10 mM MgCl2, 0.5 mM DTT, 0.5 mM ATP) in the presence or absence of purified recombinant 
Metnase (200 ng) and various concentrations of neoamphimedine. Reaction mixtures were incubated 
at 39 °C for an optimized time of 30 min. The reactions were then separated on a 1% agarose gel 
containing 0.5 μg/mL ethidium bromide with decatenated and catenated DNA markers (TopoGen). 
Fluorescence intensity quantitative analysis was carried out using Quantity One
® software [28] by 
calculating the percent decatenation by comparing the pixel intensities of both decatenated bands relative to 
the catenated  band. The percent  inhibition of decatenation was then determined using the   
following formula:  
%Decatenation with neo
%Inhibition Decatenation 100 1 .
%Decatenation without neo
 = − 

 
3.3. Cell Proliferation Assay 
HEK-293 cells transfected with a Metnase expression vector (HEK293-Metnase) were described 
previously [6]. A colorimetric cytotoxicity assay using sulforhodamine B was utilized to compare the 
proliferative ability of HEK293 and HEK293-Metnase cells [29].  
Briefly, cells were cultured in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10% 
FBS (Sigma, St. Louis, MO, USA), seeded at 2000 cells/100  μL/well in 96-well plates and incubated 
for 24 h. Medium was then replaced with medium containing various concentrations of neoamphimedine 
or etoposide. After 72 h treatment, cells were fixed with 10% aqueous trichloroacetic acid for 1 h at 4 °C, 
and washed 5× with 200 μL water. Dry fixed cells were stained with 0.4% sulforhodamine B in 1% 
aqueous acetic acid for 30 min, and washed 4× with 200 μL of 1% aqueous acetic acid. Dry stained 
cells were treated with 10 mM unbuffered Tris-base to extract protein-bound dye and absorbance 
readings were measured at 535 nm using a microplate reader (EnVision
®, Perkin Elmer).  
3.4. Competitive Inhibition Studies 
An ATP hydrolysis assay that quantifies inorganic phosphate through the formation of a high molar 
absorptivity complex with malachite green and molybdate was adapted for use in 384-well plates, with 
a total reaction volume of 15 μL [16]. We first utilized this assay to determine the Km of TopoIIα for 
its natural substrate, ATP, using ATP concentrations ranging 62.5–1600 μM. To measure the apparent Mar. Drugs 2011, 9  2405 
 
Km, the same reactions were repeated in the presence of 2, 5, or 10 μM neoamphimedine. Absorbance 
at 620 nm was  measured using a SpectraMax
®  Plus microtiter plate reader and SoftMax
®  Pro  
software [30]. To determine the Ki of neoamphimedine the same method was used with the following 
modifications: neoamphimedine (0.1–10 μM) in reaction buffer (without DNA and DTT) was added to 
the complete reaction buffer and pre-incubated for 10 min at 37 °C. Reactions were initiated by the 
addition of 600 μM ATP and incubated for 30 min at 37 °C. Reactions were terminated and measured 
as described. The IC50  value was determined and the Ki  was calculated using the Cheng-Prusoff 
equation [31]. Experiments were repeated in duplicate and Prism
® software [32] was used to perform 
non-linear fits (method of least squares) to the Michaelis-Menten kinetic model (for Km and Vmax 
values) or the dose-response inhibition model (for IC50 values). 
3.5. Molecular Docking of Neoamphimedine and Amphimedine with TopoIIα 
The 1.87 Å crystal structure of the ATPase domain of human TopoIIα (PDB: 1ZXM, [4]) was 
applied using the CHARMm force field [33], and residues were corrected for physiological pH. The 
binding site was defined as whole residues within an 8 Å radius subset encompassing the ATPase site. 
LigandFit and Flexible Docking protocols were used for the molecular docking of neoamphimedine 
into the defined binding site of TopoIIα [34]. Grid resolution was set to 0.5 Å and electrostatic energy 
was included in the calculation of the ligand internal energy. In order to avoid identical conformations, 
a root mean square deviation threshold of 1.5 Å and a score threshold of 20 kcal/mol were used. Fifty 
structural outputs were specified and the identification of a docked conformation was followed by a 
minimization using the conjugate gradient method to a convergence of 0.001 kcal/mol to optimize 
ligand-protein interactions. The Poisson-Boltzmann method was used to calculate binding energy, with 
a non-bonded list radius of 12  Å. The top-ranked conformations for each docked complex were 
selected on the following criteria: calculated binding energy, and hydrogen bond interactions between 
the protein and ligand. 
4. Conclusions  
In conclusion, the in vitro, cell based, and in silico studies presented characterize neoamphimedine 
as an ATP-competitive inhibitor of TopoIIα. These studies show that neoamphimedine can overcome 
drug resistance observed with conventional TopoIIα poisons due to TopoIIα-Metnase protein interactions. 
Molecular modeling has elucidated the pharmacophore of neoamphimedine, most notably the position 
of the E ring carbonyl and the resulting hydrogen bond with Ser148.  Finally, it is reasonable to 
conclude that Metnase likely binds TopoIIα near the DNA binding site located in the cleavage and 
relegation domain, which prevents or alters TopoIIα poison binding but does not block access to the  
N-terminal ATPase binding sites of TopoIIα, which is logical given that TopoIIα must hydrolyze ATP 
during catalytic function [14,15]. These results support the continued development of neoamphimedine 
as a novel catalytic inhibitor of TopoIIα for the treatment of cancer. 
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